GLP-1 therapies just got a whole lot less expensive for patients who pay out of pocket. Eli Lilly’s Zepbound (tirzepatide) single-dose vials are now available at rates similar to compounded versions of semaglutide. Patients can now access a four-week supply of Zepbound for as little as $399 for the 2.5 mg dose and $549 for…
Can payers afford the new era of GLP-1 drugs? Or can they afford not to?
The latest crop of glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide and tirzepatide (technically, a dual GIP/GLP-1 receptor agonist), have upended the way we treat metabolic disorders, including obesity. These drugs mimic gut hormones, improving blood sugar control and often leading to significant weight loss. But as Kyasha Sri Ranjan, Ph.D., engagement manager at Lifescience…
High-profile drugs under the legal spotlight in 2023
In the wake of the COVID-19 pandemic, the U.S. has witnessed a surge in litigation. One factor driving the uptick in the pharmaceutical sector is the rise of copycat litigation. As mass tort activity amplifies, plaintiff lawyers are treating previously filed lawsuits as templates for new claims. Examples of the trend include steadily increasing nitrosamines…